Third Harmonic Bio Stock Today
| THRD Stock | USD 3.60 0.17 4.96% |
PerformanceVery Weak
| Odds Of DistressLow
|
Third Harmonic is trading at 3.60 as of the 18th of February 2025, a 4.96% up since the beginning of the trading day. The stock's lowest day price was 3.45. Third Harmonic has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 1st of March 2023 and ending today, the 18th of February 2025. Click here to learn more.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts. The company has 45.06 M outstanding shares of which 3.57 M shares are at this time shorted by private and institutional investors with about 12.68 trading days to cover. More on Third Harmonic Bio
Moving against Third Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Third Stock Highlights
Third Harmonic Bio (THRD) is traded on NASDAQ Exchange in USA. It is located in 1700 Montgomery Street, San Francisco, CA, United States, 94111 and employs 51 people. Third Harmonic is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 162.21 M. Third Harmonic Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 45.06 M outstanding shares of which 3.57 M shares are at this time shorted by private and institutional investors with about 12.68 trading days to cover.
Third Harmonic Bio currently holds about 112.73 M in cash with (20.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Third Harmonic Probability Of Bankruptcy
Ownership AllocationThird Harmonic Bio shows a total of 45.06 Million outstanding shares. The majority of Third Harmonic Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Third Harmonic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Third Harmonic Bio. Please pay attention to any change in the institutional holdings of Third Harmonic Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly six hundred seventy-one thousand three hundred seventy invesors are currently shorting Third Harmonic expressing very little confidence in its future performance.
Check Third Ownership Details
Third Harmonic Bio Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Third Harmonic market risk premium is the additional return an investor will receive from holding Third Harmonic long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.17) | |||
| Jensen Alpha | (1.77) | |||
| Total Risk Alpha | (1.78) | |||
| Treynor Ratio | (1.35) |
Third Stock Against Markets
Third Harmonic Corporate Management
| Robert Ho | Chief Officer | Profile | |
| Christopher Dinsmore | Chief Officer | Profile | |
| Dennis Dean | Chief Officer | Profile | |
| Gregg Keaney | VP Devel | Profile | |
| Christopher Murphy | Chief Officer | Profile | |
| Adrian Ray | Chief Officer | Profile | |
| Ommer Chohan | Treasurer Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Third Harmonic Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Third Harmonic. If investors know Third will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Third Harmonic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Third Harmonic Bio is measured differently than its book value, which is the value of Third that is recorded on the company's balance sheet. Investors also form their own opinion of Third Harmonic's value that differs from its market value or its book value, called intrinsic value, which is Third Harmonic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Third Harmonic's market value can be influenced by many factors that don't directly affect Third Harmonic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Third Harmonic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Third Harmonic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Third Harmonic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.